Insilico Medicine ٢٠ أبريل ٢٠٢٦ Insilico Medicine Advances AI-Driven Target Discovery with Validated TargetPro–TargetBench Framework - Insilico Medicine
Insilico Medicine ٢٠ أبريل ٢٠٢٦ Insilico Medicine Showcases AI Drug Discovery Platform at AACR 2026 - TipRanks
Insilico Medicine ٢٩ مارس ٢٠٢٦ Insilico Medicine Announces 2025 Annual Results, Redefining Value Delivery in AI-Powered Drug Discovery - Insilico Medicine
Endpoints News ٢٧ يناير ٢٠٢٦ Insilico’s latest deal is a $120M cardiometabolic drug discovery pact with Qilu Pharma
FierceBiotech ٢٧ يناير ٢٠٢٦ Qilu programs path into cardiometabolic disease with $120M, AI-enabled Insilico alliance
Endpoints News ٢١ يناير ٢٠٢٦ Fosun-funded Hygtia Therapeutics licenses Insilico’s NLRP3 inhibitor for Parkinson’s